Cargando…

Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials

PURPOSE: The upper tolerable intake level for vitamin D in the general population has been set at 4000 international units (IU) daily, but considerable uncertainty remains. We summarized reported harmful effects of a daily vitamin D supplement of 3200–4000 IU in trials lasting ≥ 6 months. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Zittermann, Armin, Trummer, Christian, Theiler-Schwetz, Verena, Pilz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195747/
https://www.ncbi.nlm.nih.gov/pubmed/36853379
http://dx.doi.org/10.1007/s00394-023-03124-w
_version_ 1785044197723602944
author Zittermann, Armin
Trummer, Christian
Theiler-Schwetz, Verena
Pilz, Stefan
author_facet Zittermann, Armin
Trummer, Christian
Theiler-Schwetz, Verena
Pilz, Stefan
author_sort Zittermann, Armin
collection PubMed
description PURPOSE: The upper tolerable intake level for vitamin D in the general population has been set at 4000 international units (IU) daily, but considerable uncertainty remains. We summarized reported harmful effects of a daily vitamin D supplement of 3200–4000 IU in trials lasting ≥ 6 months. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials in several databases and identified 22 trials reporting safety data. Parameters of calcium metabolism, falls, hospitalization, and mortality were assessed. RESULTS: The selected trials comprised a total number of 12,952 participants. All trials used supplemental vitamin D(3). The relative risk (RR) of hypercalcemia in the vitamin D vs. control arm was 2.21 (95%CI: 1.26–3.87; 10 studies), with a vitamin D-induced frequency of hypercalcemia of 4 cases per 1000 individuals. Subgroup analysis in trials with > 100 and ≤ 100 study participants revealed an RR of 2.63 (95%CI: 1.30–5.30; 7 studies) and 0.80 (95%CI: 0.24–2.62; 3 studies), respectively (P(interaction) = 0.06). Risks of falls and hospitalization were also significantly increased in the vitamin D arm with an RR of 1.25 (95%CI: 1.01–1.55; 4 studies) and 1.16 (95%CI: 1.01–1.33; 7 studies), respectively. Risks of hypercalciuria, kidney stones, and mortality did not differ significantly between study arms. Quality assessment revealed high risk of incomplete reporting of safety-related outcome data. CONCLUSION: Supplemental vitamin D doses of 3200–4000 IU/d appear to increase the risk of hypercalcemia and some other adverse events in a small proportion of individuals, indicating that this dose is not completely safe. In future studies, rigorous reporting of safety-related outcomes is needed when using moderately high doses of vitamin D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00394-023-03124-w.
format Online
Article
Text
id pubmed-10195747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101957472023-05-20 Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials Zittermann, Armin Trummer, Christian Theiler-Schwetz, Verena Pilz, Stefan Eur J Nutr Original Contribution PURPOSE: The upper tolerable intake level for vitamin D in the general population has been set at 4000 international units (IU) daily, but considerable uncertainty remains. We summarized reported harmful effects of a daily vitamin D supplement of 3200–4000 IU in trials lasting ≥ 6 months. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials in several databases and identified 22 trials reporting safety data. Parameters of calcium metabolism, falls, hospitalization, and mortality were assessed. RESULTS: The selected trials comprised a total number of 12,952 participants. All trials used supplemental vitamin D(3). The relative risk (RR) of hypercalcemia in the vitamin D vs. control arm was 2.21 (95%CI: 1.26–3.87; 10 studies), with a vitamin D-induced frequency of hypercalcemia of 4 cases per 1000 individuals. Subgroup analysis in trials with > 100 and ≤ 100 study participants revealed an RR of 2.63 (95%CI: 1.30–5.30; 7 studies) and 0.80 (95%CI: 0.24–2.62; 3 studies), respectively (P(interaction) = 0.06). Risks of falls and hospitalization were also significantly increased in the vitamin D arm with an RR of 1.25 (95%CI: 1.01–1.55; 4 studies) and 1.16 (95%CI: 1.01–1.33; 7 studies), respectively. Risks of hypercalciuria, kidney stones, and mortality did not differ significantly between study arms. Quality assessment revealed high risk of incomplete reporting of safety-related outcome data. CONCLUSION: Supplemental vitamin D doses of 3200–4000 IU/d appear to increase the risk of hypercalcemia and some other adverse events in a small proportion of individuals, indicating that this dose is not completely safe. In future studies, rigorous reporting of safety-related outcomes is needed when using moderately high doses of vitamin D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00394-023-03124-w. Springer Berlin Heidelberg 2023-02-28 2023 /pmc/articles/PMC10195747/ /pubmed/36853379 http://dx.doi.org/10.1007/s00394-023-03124-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Contribution
Zittermann, Armin
Trummer, Christian
Theiler-Schwetz, Verena
Pilz, Stefan
Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title_full Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title_fullStr Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title_full_unstemmed Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title_short Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
title_sort long-term supplementation with 3200 to 4000 iu of vitamin d daily and adverse events: a systematic review and meta-analysis of randomized controlled trials
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195747/
https://www.ncbi.nlm.nih.gov/pubmed/36853379
http://dx.doi.org/10.1007/s00394-023-03124-w
work_keys_str_mv AT zittermannarmin longtermsupplementationwith3200to4000iuofvitaminddailyandadverseeventsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT trummerchristian longtermsupplementationwith3200to4000iuofvitaminddailyandadverseeventsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT theilerschwetzverena longtermsupplementationwith3200to4000iuofvitaminddailyandadverseeventsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT pilzstefan longtermsupplementationwith3200to4000iuofvitaminddailyandadverseeventsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials